Artemis Medicare Q1 FY27 Results (NSE: ARTEMISMED)
Signal: Margin expansion
The read
Q1FY27 consolidated revenue ₹287.32 Cr (+12.7% YoY), EBITDA margin expanded to 21.5% (+526bps YoY), PAT ₹31.31 Cr (+47.1% YoY). The company also announced a ₹160-180 Cr expansion plan to add 200+ beds at its flagship Gurugram hospital. The QoQ figures from the block appear inconsistent, but the underlying trend shows strong YoY growth and margin improvement. This is the highest EBITDA margin in the last 12 quarters, indicating a step-change in profitability.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹287.32 Cr | 12.7% | -73.4% |
| EBIT | ₹49.09 Cr | 32.1% | |
| Net profit | ₹31.31 Cr | 47.1% | |
| EPS | ₹1.98 | 46.7% | |
| EBIT margin | 21.5% |
P&L walk
Revenue grew 12.7% YoY, EBITDA margin expanded 526bps to 21.5% on better cost control and operating leverage, driving PAT up 47.1% YoY.
Key positives
- Revenue growth of 12.7% YoY to ₹287.32 Cr
- EBITDA margin expanded 526bps to 21.5%, highest in last 12 quarters
- PAT up 47.1% YoY to ₹31.31 Cr
- Occupancy at 65.7% with expansion plan to add 200+ beds
- Strong operating leverage evident from cost control
Key concerns
- QoQ growth figures from the block appear erroneous (-73.4% revenue QoQ is inconsistent with sequential increase; actual QoQ revenue growth is ~3%)
- High valuation at P/E 44.9x
Research and educational content only. Not investment advice.